FAP and neoplasm: As expected, a single dose of 177Lu-DOTA-4P(FAPI)4 demonstrated excellent antitumor ability in HT-1080-FAP tumor–bearing mice, whereas the tumors continued to grow in the control and 177Lu-FAPI-46 therapy groups.